OrbiMed Advisors CMMB Position
ExitedOrbiMed Advisors exited their position in Chemomab Therapeutics Ltd. (CMMB) in Q3 2025, after holding the stock for 11 quarters.
The position was first reported in Q1 2023 and has been tracked across 11 quarterly 13F filings.
1 other tracked fund also holds CMMB.
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Full company profile →Short Interest
0.6%
0.4 days to cover
OrbiMed Advisors CMMB Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q3 2025 | Exited | 0 | -940,990 | $0 |
| Q2 2025 | Decreased | 940,990 | -800,283 | $1.1M |
| Q1 2025 | Held | 1,741,273 | — | $1.9M |
| Q4 2024 | Held | 1,741,273 | — | $3.2M |
| Q3 2024 | Decreased | 1,741,273 | -500,000 | $2.7M |
| Q2 2024 | Decreased | 2,241,273 | -1 | $2.0M |
| Q1 2024 | Held | 2,241,274 | — | $1.7M |
| Q4 2023 | Held | 2,241,274 | — | $1.1M |
| Q3 2023 | Held | 2,241,274 | — | $2.0M |
| Q2 2023 | Held | 2,241,274 | — | $2.9M |
| Q1 2023 | New | 2,241,274 | +2,241,274 | $3.6M |
Frequently Asked Questions
Does OrbiMed Advisors own CMMB?
No. OrbiMed Advisors exited their position in Chemomab Therapeutics Ltd. (CMMB) in Q3 2025. They previously held the stock for 11 quarters.
How many hedge funds own CMMB?
1 specialist biotech hedge fund currently holds CMMB, including Cormorant Asset Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy CMMB?
OrbiMed Advisors's position in CMMB was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's CMMB position increasing or decreasing?
OrbiMed Advisors completely exited their CMMB position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CMMBCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →